Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from Oncolytics Biotech ( (TSE:ONC) ).
Oncolytics Biotech Inc. has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, as its stock has traded below $1.00 for 30 consecutive business days. The company has until August 12, 2025, to regain compliance, during which its shares will continue to trade on Nasdaq. If Oncolytics fails to meet the requirement by then, it may qualify for an additional compliance period. The notification does not immediately affect the company’s operations or stock listing, but it highlights the need to address market value concerns, potentially impacting investor confidence.
More about Oncolytics Biotech
Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent. The company targets oncology, particularly metastatic breast cancer and pancreatic cancer, with pelareorep showing promising results in various clinical trials. Oncolytics aims to advance pelareorep through combination clinical trials and towards registrational studies, having received Fast Track designation from the FDA for these cancers.
YTD Price Performance: -16.99%
Average Trading Volume: 1,220,762
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $59.75M
See more data about ONC stock on TipRanks’ Stock Analysis page.
